Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2022 | The promise of CRISPR-based gene editing therapy for hATTR amyloidosis

Marcus Anthony Urey • 6 Sep 2022
ISA 2022
Amyloidosis Rare Diseases

Marcus Anthony Urey, MD, University of California, San Diego, CA, talks on the potential of CRISPR-based gene-editing therapy for patients with hereditary transthyretin-mediated (hATTR) amyloidosis. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consultancy: Alnylam, Akcea, BridgeBio
Honoraria: Pfizer
Research support: Ionis

More from Marcus Anthony Urey

1:08
The multidisciplinary management of hATTR amyloidosis
Marcus Anthony Urey • 6 Sep 2022
0:54
RNAi therapy in patients with hATTR amyloidosis with cardiac and neurologic involvement
Marcus Anthony Urey • 6 Sep 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals